Eli Lilly and Company (SWX:LLY)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 855.13B +52.2% |
| Revenue (ttm) | 57.95B +47.4% |
| Net Income | 20.28B +127.6% |
| EPS | 22.58 +129.1% |
| Shares Out | n/a |
| PE Ratio | 42.18 |
| Forward PE | 32.12 |
| Dividend | 5.07 (0.51%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | n/a |
| Open | n/a |
| Previous Close | 965.00 |
| Day's Range | n/a |
| 52-Week Range | 560.00 - 990.00 |
| Beta | 0.51 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
It's been three months since Lilly launched its obesity pill. Most people are taking Novo's pill instead.
The market leader in obesity shots, Lilly hasn't made a major dent in the pill market yet.
Study flags need to monitor frailty risks with GLP-1 drugs for older adults
Potential signs of frailty in older adults taking Eli Lilly's GLP-1 obesity drug Zepbound may signal relatively high risks for adverse outcomes, according to a large study that underscores concerns a...
Retevmo granted FDA traditional approval for RET fusion-positive solid tumors
The Food and Drug Administration granted traditional approval to selpercatinib or Retevmo, from Eli Lilly (LLY), for adult and pediatric patients two years of age and older with locally advanced…
Is Lilly Stock On Track To Hit $2,090?
This article was written by Doug Nathman, with research by his team at Trefis.
Eli Lilly price target raised to $1,385 from $1,300 at Bernstein
Bernstein raised the firm’s price target on Eli Lilly (LLY) to $1,385 from $1,300 and keeps an Outperform rating on the shares. Eli Lilly shares have performed strongly in Q2…
Eli Lilly Stock (LLY) Gets a Price Target Boost Heading into Earnings
The pharma giant reports financial results on Aug. 5.
Eli Lilly price target raised to $1,425 from $1,250 at UBS
UBS raised the firm’s price target on Eli Lilly (LLY) to $1,425 from $1,250 and keeps a Buy rating on the shares.
Eli Lilly price target raised to $1,273 from $1,235 at Guggenheim
Guggenheim raised the firm’s price target on Eli Lilly (LLY) to $1,273 from $1,235 and keeps a Buy rating on the shares after updating the firm’s model ahead of Q2…
Eli Lilly price target raised to $1,334 from $1,251 at BofA
BofA raised the firm’s price target on Eli Lilly (LLY) to $1,334 from $1,251 and keeps a Buy rating on the shares. Second quarter results are expected to highlight stronger…
Eli Lilly price target raised to $1,370 from $1,281 at Truist
Truist raised the firm’s price target on Eli Lilly (LLY) to $1,370 from $1,281 and keeps a Buy rating on the shares ahead of its Q2 results. The quarter could…
Eli Lilly to presents abstracts at 2026 AAIC on Kisunla trials
Eli Lilly (LLY) announced it will present 16 abstracts at the 2026 Alzheimer’s Association International Conference, AAIC,, July 12-15 in London. Three oral presentations anchor the scientific program...
Lilly to present Alzheimer's disease diagnostic and therapeutic research at AAIC 2026, including new data on P-tau217 blood tests and amyloid-targeting treatment
Analyses across Kisunla (donanemab-azbt) trials providing further insights into the benefit-risk profile from long-term extension data New data compares the diagnostic performance of P-tau217 blood te...
Eli Lilly Stock (LLY) Gets a Boost as Eczema Treatment Receives a Positive Recommendation in Canada
There is more to the company than weight-loss drugs.
Strong LLY News Boosts Active Healthcare ETF GDOC
Healthcare and technology provide an intriguing contrast. Many healthcare stocks are traditionally known for their more defensive uses in portfolios.
Eli Lilly Stock (LLY) Gets a Boost as Eczema Treatment Receives a Positive Recommendation in Canada
There is more to the company than weight-loss drugs.
Eli Lilly price target raised to $1,500 from $1,250 at RBC Capital
RBC Capital raised the firm’s price target on Eli Lilly (LLY) to $1,500 from $1,250 and keeps an Outperform rating on the shares in a preview of its Q2 results.
Eli Lilly price target raised to $1,347 from $1,344 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Eli Lilly (LLY) to $1,347 from $1,344 and keeps an Overweight rating on the shares. Biotech could benefit from…
Health Canada approves Eli Lilly’s Mounjaro for use in children 10 years old
Eli Lilly (LLY) Canada announced that Mounjaro is now indicated as an adjunct to diet and exercise to improve glycemic control in pediatric patients living with type 2 diabetes aged…
Eli Lilly price target raised to $1,400 from $1,300 at JPMorgan
JPMorgan raised the firm’s price target on Eli Lilly (LLY) to $1,400 from $1,300 and keeps an Overweight rating on the shares. The firm sees potential upside for Mounjaro from…
Eli Lilly price target raised to $1,350 from $1,230 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Eli Lilly (LLY) to $1,350 from $1,230 and keeps an Overweight rating on the shares. Large-cap biopharmas are expected to report broadly…
AI Is the Ultimate Growth Tailwind for Eli Lilly (LLY). Here’s Why
Artificial intelligence (AI) could prove to be a huge long-term growth tailwind for Eli Lilly ($LLY), as it’s transforming the company’s multi-decade trajectory. AI is changing how the company discove...
Several Analysts Pounds the Table on Eli Lilly Stock (LLY) Heading into Earnings
The company has several catalysts to drive its share price higher.
Eli Lilly Hits Highs on GLP-1 Medicare Inclusion, Huge Results
Eli Lilly and Company (LLY) shares up 18,585% since Big Money bought big in 1990.
Medicare will start covering obesity drugs for the first time. Here's what patients should know
Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge. The move could unlock a vast new...
China's Innovent Biologics gains commercialization rights for Eli Lilly breast cancer drug
Innovent Biologics has entered into an agreement that grants it sole commercialization rights for Eli Lilly's breast cancer drug Verzenios in mainland China, the Chinese drugmaker said Tues...